Gomes Anita Q, Correia Daniel V, Silva-Santos Bruno
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal.
EMBO Rep. 2007 Nov;8(11):1024-30. doi: 10.1038/sj.embor.7401090.
Tumours develop in vertebrate organisms endowed with immune systems that are potentially able to eradicate them. Nevertheless, our ever-increasing understanding of the complex interactions between lymphocytes and tumour cells fuels the long-standing hope of developing efficient immunotherapies against cancer. This review focuses on a versatile family of proteins, the major histocompatibility complex class Ib, which has been recently implicated in both the establishment of anti-tumour immune responses and in tumour immune response evasion. We focus on a subset of class Ib proteins, human leukocyte antigen (HLA)-G, Qa-2, CD1d and NKG2D ligands, which bind to either stimulatory or inhibitory receptors expressed on T, natural killer (NK) and NKT lymphocytes, and thereby modulate their anti-tumour activity.
肿瘤在具有免疫系统的脊椎动物体内发展，而免疫系统有潜在能力根除肿瘤。然而，我们对淋巴细胞与肿瘤细胞之间复杂相互作用的理解不断加深，这燃起了长期以来开发有效抗癌免疫疗法的希望。本综述聚焦于一类多功能蛋白质家族，即主要组织相容性复合体Ib类，其最近被认为既参与抗肿瘤免疫反应的建立，也参与肿瘤免疫反应逃逸。我们重点关注Ib类蛋白质的一个子集，即人类白细胞抗原（HLA）-G、Qa-2、CD1d和NKG2D配体，它们与T细胞、自然杀伤（NK）细胞和NKT淋巴细胞上表达的刺激性或抑制性受体结合，从而调节它们的抗肿瘤活性。
